Moffitt Cancer Center and Cryoport Announce Strategic Collaboration for Advanced Biorepository Services
Moffitt Cancer Center, a leading National Cancer Institute-designated comprehensive cancer centre, has announced a strategic partnership with Cryoport, Inc., a global leader in supply chain
Vetter Announces Upcoming Launch of V-OVS Next Syringe Closure System
Vetter a globally operating Contract Development and Manufacturing Organization (CDMO), has revealed plans for the upcoming launch of the V-OVS next, a next-generation version of
Emergent BioSolutions Secures Exclusive Rights to KLOXXADO in U.S. and Canada
Emergent BioSolutions, a leading biopharmaceutical company, has announced an exclusive six-year agreement with Hikma Pharmaceuticals to distribute KLOXXADO Nasal Spray in the United States and
Touchlight Achieves GMP Certification for UK Synthetic DNA Facility
Touchlight, an innovation-focused Contract Development and Manufacturing Organisation (CDMO), has announced GMP certification of its facility in Hampton, UK. The achievement positions the company as
Eckert & Ziegler Expands Collaboration with GlyTherix to Supply Actinium-225 for Clinical Trials
Eckert & Ziegler has signed a global supply agreement with GlyTherix Ltd to provide Actinium-225 (Ac-225) in support of the latter’s clinical research and development
ITM and Ariceum Sign Agreement to Supply Actinium-225 for Cancer Treatments
ITM Isotope Technologies Munich SE (ITM) has announced a supply agreement with Ariceum Therapeutics to deliver non-carrier-added (n.c.a.) Actinium-225 (Ac-225) for use in the development
XingImaging, a MITRO company, Opens State-of-the-Art Research Facility in New Haven
XingImaging, a MITRO company, has expanded its operations with the opening of a new, state-of-the-art research facility in New Haven, Connecticut. The new site, which
BioCina and NovaCina Merge to Create End-to-End CDMO Solutions
BioCina, a global contract development and manufacturing organisation (CDMO), has announced a strategic merger with NovaCina. The merger integrates both companies’ expertise to deliver a
Alcami Corporation Announces Leadership, Appoints Patrick Walsh as Interim CEO
Alcami Corporation, a contract development and manufacturing organisation (CDMO), has announced the resignation of its CEO, Bill Humphries. Effective immediately, Patrick Walsh, the company’s Board
Cytovance Biologics and PolyPeptide Partner to Advance Peptide Drug Development
Cytovance Biologics and PolyPeptide have entered into a strategic collaboration to support the development and manufacturing of microbial and mammalian-expressed peptide drugs. This partnership combines
Stay ahead of trends and best practices
